ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,620.84
0.21%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Outlook Therapeutics Inc (OTLK)

  7. Outlook Therapeutics Inc (OTLK) Noticias

OTLK

Outlook Therapeutics (OTLK)

Outlook Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:OTLK
FechaHoraFuenteTítuloSímboloCompañía
28/05/202407:05GlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
15/05/202416:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
15/05/202416:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
15/05/202416:00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
13/05/202407:50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
09/05/202407:45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKOutlook Therapeutics Inc
06/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OTLKOutlook Therapeutics Inc
06/05/202415:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OTLKOutlook Therapeutics Inc
02/05/202408:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKOutlook Therapeutics Inc
29/04/202408:00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKOutlook Therapeutics Inc
15/04/202415:15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKOutlook Therapeutics Inc
22/03/202406:35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
18/03/202416:10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKOutlook Therapeutics Inc
12/03/202407:05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKOutlook Therapeutics Inc
11/03/202415:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
14/02/202407:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202406:00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202405:59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
31/01/202415:01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
31/01/202407:05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKOutlook Therapeutics Inc
29/01/202416:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
24/01/202416:00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
23/01/202407:00GlobeNewswire Inc.Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010NASDAQ:OTLKOutlook Therapeutics Inc
22/12/202316:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OTLKOutlook Therapeutics Inc
22/12/202307:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUNASDAQ:OTLKOutlook Therapeutics Inc
19/12/202307:05GlobeNewswire Inc.Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NASDAQ:OTLKOutlook Therapeutics Inc
18/12/202304:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)NASDAQ:OTLKOutlook Therapeutics Inc
06/12/202307:05GlobeNewswire Inc.Outlook Therapeutics® Announces Strategic Organizational RealignmentNASDAQ:OTLKOutlook Therapeutics Inc
27/11/202307:05GlobeNewswire Inc.Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010NASDAQ:OTLKOutlook Therapeutics Inc
14/11/202307:05GlobeNewswire Inc.Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of EuropeNASDAQ:OTLKOutlook Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OTLK

Su Consulta Reciente

NASDAQ
NVDA
NVIDIA
CCOM
US500
US 500
NYSE
JPM
JP Morgan Chase
CCOM
OILBRENT
Brent Oil
NYSE
BAC
Bank of America
NYSE
DIS
Walt Disney
NYSE
CVX
Chevron
AMEX
SPY
SPDR S&P 500
PM
XAUUSD
Gold vs US Dollar
NASDAQ
MSFT
Microsoft
NASDAQ
TSLA
Tesla
NYSE
VZ
Verizon Communications
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
AMZN
Amazon.com
USI
USTECH100
US Tech 100
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados